comparemela.com

Latest Breaking News On - Arthura levin - Page 1 : comparemela.com

Arthur A. Levin Sells 40,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the transaction, the director now directly owns […]

Los-angeles
California
United-states
Florida
America
Arthura-levin
Los-angeles-capital-management
Proshare-advisors
Cantor-fitzgerald
Avidity-biosciences-company-profile
Avidity-biosciences-inc

Avidity Biosciences (NASDAQ:RNA) Trading Down 4.3%

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) traded down 4.3% on Tuesday . The stock traded as low as $26.07 and last traded at $26.27. 447,285 shares were traded during mid-day trading, a decline of 60% from the average session volume of 1,124,135 shares. The stock had previously closed at $27.45. Analyst […]

United-states
China
America
Arthura-levin
Quadrant-capital-group
Privium-fund-management
Nisa-investment-advisors
Nasdaq
Avidity-biosciences-company-profile
Janney-montgomery-scott
Avidity-biosciences-inc

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $41.33 Consensus PT from Brokerages

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last […]

United-states
China
America
Sarah-boyce
Arthura-levin
Quadrant-capital-group
Daiwa-securities-group-inc
Needham-company
Nisa-investment-advisors
Cantor-fitzgerald
China-universal-asset-management-co
Securities-exchange-commission

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by Brokerages

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is […]

United-states
America
Arthura-levin
Sarah-boyce
Avidity-biosciences-inc
Vanguard-group-inc
Needham-company
Nasdaq
Cantor-fitzgerald
Avoro-capital-advisors
Pricet-rowe-associates-inc
Avidity-biosciences

Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $149,500.00 in Stock

Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $149,500.00 in Stock
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Arthura-levin
Cantor-fitzgerald
Avidity-biosciences-inc
Needham-company
Pricet-rowe-associates-inc
Vanguard-group-inc
Avoro-capital-advisors
Nasdaq
Avidity-biosciences

vimarsana © 2020. All Rights Reserved.